Non-vitamin K antagonist oral anticoagulants may be associated with lower risks for adverse events requiring hospitalization and reduced rates of major bleeding compared with vitamin K antagonists in patients receiving PCI for non-valvular atrial fibrillation who have an indication for anticoagulation.
Researchers examined the association of blood levels of hydroxychloroquine with thrombotic events in a longitudinal systemic lupus erythematous cohort.
Findings show the need for studies addressing the role of anticoagulation therapy in postoperative atrial fibrillation after left-sided heart valve surgery.
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
The severity of lung disease in preterm infants with bronchopulmonary dysplasia and pulmonary hypertension undergoing cardiac catheterization did not correlate with mortality.
Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.
The neural network developed in this study yielded a false-negative rate of 0.22%.
Investigators examined a link between major cardiovascular risk factors, such as older age and smoking, and venous thromboembolism, consisting of deep vein thrombosis or pulmonary embolism.
Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.